B. Braun News

Product Quick Finder

Choose a category or subcategory

B. Braun Showcases Market Leading Regional Anesthesia Portfolio At ASA 2019

BETHLEHEM, PA – October 17, 2019 — B. Braun Medical Inc. (B.Braun), the U.S. market leader in Regional Anesthesia¹, will showcase its robust Regional Anesthesia portfolio at this year’s Anesthesiology Annual Meeting (ASA) from October 19-23 in Orlando, Florida.

In a simulated hospital setting at booth #1540, B.Braun will showcase the following products:

  • Xperius® Point-of-Care Ultrasound System: The ultrasound system is designed to support the needs in regional anesthesia at the point of care. The system is designed to offer an intuitive user interface and image quality for needle targeting and positioning, as well as ergonomic features such as an articulating arm. Xperius' imaging complements B.Braun's regional block portfolio. Xperius is the first product resulting from a strategic alliance between B. Braun and Royal Philips (NYSE: PHG, AEX: PHIA).
  • Stimuplex® Ultra 360® Nerve Block Needles: Stimuplex Ultra 360 needles feature B.Braun’s echogenic 360º X-pattern. The ‘X’ is a unique shape, which when combined with a clear coating, reflects more ultrasound waves back to the probe than previous designs.² These needles are designed to provide visibility without compromising puncture characteristics.
  • Drugs Are Back in Regional Anesthesia Trays: As the U.S. leader in Regional Anesthesia¹, we have invested heavily since 2015 in initiatives to help ensure a stable drug supply and reduce the risk of tray backorders associated with drug shortages.
  • Clorotekal® (chloroprocaine hydrochloride): B.Braun launched its first FDA- approved local anesthetic, Clorotekal® (chloroprocaine hydrochloride*). Clorotekal is indicated for intrathecal injection for the production of subarachnoid block (spinal anesthesia) in adults undergoing spinal anesthesia. It is available in 50 mg/ 5 mL glass ampules. See below for indications, contraindications, and Full Prescribing Information.

“Our top priority is patient care,” said Pete McGregor, Director of Marketing for Pain Control. “We are dedicated to helping clinicians optimize the regional anesthesia process by adding products to our robust therapy portfolio that address post-operative pain and help reduce the use of opioids,” McGregor continued.

Clorotekal (chloroprocaine hydrochloride) is indicated for intrathecal injection for the production of subarachnoid block (spinal anesthesia) in adults undergoing surgical procedures. Indicated procedures include those suitable for Clorotekal’s short duration of action. Clorotekal is available in 50 mg/5 mL glass ampules. Doses above 50 mg have not been adequately tested for efficacy and safety. Please see prescribing information attached.

Contraindications: Known hypersensitivity to the active substance, medicinal products of the PABA (para-aminobenzoic acid) ester group, other ester-type local anesthetics or to any of the excipients. General and specific contraindications to spinal anesthesia regardless of the local anesthetic used should be taken into account (e.g., decompensated cardiac insufficiency, hypovolemic shock, coagulopathy). Intravenous regional anesthesia (the anesthetic agent is introduced into the limb and allowed to set in while tourniquets retain the agent within the desired area). Serious problems with cardiac conduction. Local infection at the site of proposed lumbar puncture and septicemia.

Please see Important Safety Information for Clorotekal that follows.

For additional information, please see Full Prescribing Information and healthcare provider information for Clorotekal (chloroprocaine hydrochloride) at www.clorotekalusa.com.

*Clorotekal is a registered trademark of Sintetica S.A. and is manufactured for B. Braun Medical Inc.

About B. Braun

B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture, ostomy and wound care, and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.

Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website.


¹ 2018Q2 All Regional Anesthesia Products – Total Market HC & OPM Dollars (GHX, IQVIA [MDSA] & B. Braun Data On File)

 ² Internal testing: ETRs NPAK-A8TP7B